Risk factors for hyperlactataemia in HIV-infected patients, Aquitaine Cohort, 1999--2003.
The objectives of our study were to describe the characteristics of a subset of patients who had been prescribed serum lactate in clinical practice within a large cohort of HIV-infected patients and to determine the factors associated with hyperlactataemia. Hyperlactataemia (> or =2 mmol/l) was found in 219 [29% (95% confidence interval: 25.3-31.7)] of the 768 HIV-infected participants. In multivariate analysis (logistical regression), an increased risk of hyperlactataemia was associated with increasing age, CD4 count <500/mm3, triglycerides >2.2 mmol/L, lipoatrophy and stavudine use. In a second model coding for the NRTI-based drug combinations, only those including stavudine were associated with an increased risk of hyperlactataemia. In a third model including exposure duration to NRTIs, we estimated a 20% increased risk of hyperlactataemia per year of exposure to didanosine or stavudine. The risk of hyperlactataemia could increase over time in patients treated with these drugs and is also closely associated with increased age, decreased CD4 count, lipodystrophy and increased plasma triglycerides. It could be proposed that patients having one or more of these risk factors undergo regular monitoring of plasma lactate and renal function to prevent lactic acidosis.
Bonnet
Fabrice
F
Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint-André, Bordeaux, France. fabrice.bonnet@chu-bordeaux.fr
Balestre
Eric
E
Bernardin
Elise
E
Pellegrin
Jean-Luc
JL
Neau
Didier
D
Dabis
François
F
D000140:Acidosis, Lactic / Q000139:chemically induced*; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy; D000328:Adult; D000367:Age Factors; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000494:pharmacology; D015704:CD4 Antigens / Q000097:blood; D015331:Cohort Studies; D016049:Didanosine / Q000009:adverse effects / Q000494:pharmacology; D004359:Drug Therapy, Combination; D039682:HIV-Associated Lipodystrophy Syndrome / Q000209:etiology; D006801:Humans; D019344:Lactic Acid / Q000097:blood*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D018119:Stavudine / Q000009:adverse effects* / Q000494:pharmacology; D014280:Triglycerides / Q000097:blood
D019380:Anti-HIV Agents; D015704:CD4 Antigens; D018894:Reverse Transcriptase Inhibitors; D014280:Triglycerides; D019344:Lactic Acid; D018119:Stavudine; D016049:Didanosine